OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-03-31-accounts

Company no. 03005230 Charity no. 1043280

M. S. Research Treatment and Education Limited

Report and Unaudited Financial Statements

31 March 2021

M. S. Research Treatment and Education Limited

Reference and administrative details

For the year ended 31 March 2021

Company number 03005230
Charity number 1043280
Registered office and The Vassall Centre
operational address Gill Avenue
Fishponds
Bristol
BS16 2QQ
Trustees Trustees, who are also directors under company law, who served during
the year and up to the date of this report were as follows:
Ben Clacy Director for Professional Health Partnerships,
Company Secretary
Rosie Jones Chair, Director for Research
Brian Pagington Community representative
Olga Pagington HR and Community representative
Laurence Robb Director for Patient Representation
Bankers CAF Bank Ltd National Westminster Bank Plc
25 Kings Hill Avenue PO Box 30038
Kings Hill Victoria Street
West Malling London
ME19 4JO SW1H 0H
Independent Godfrey Wilson Limited
examiners Chartered accountants and statutory auditors
5th Floor Mariner House
62 Prince Street
Bristol
BS1 4QD

1

M. S. Research Treatment and Education Limited

Chair's report

For the year ended 31 March 2021

The months spanning November 2019 to August 2021 have been described as a “once in a lifetime era”. Certainly, the advent of the coronavirus pandemic has changed most of our perceptions as to how medical research can be sustained, and how charitable organisations need to adapt and change to avoid being destroyed through lack of funding and the unintended consequences of the impact of Covid-19 on NHS and university research staff and resources. The impact of the pandemic on research funders was immediate and prolonged, as public fundraising events were cancelled. Other fundraising opportunities were re-focused on supporting people through the pandemic and funding research into the virus Covid-19 and its consequences for the population at large many charities faced the prospect of closure. MS Research might well have been one of the casualties of this unprecedented time had it not been for a long-standing commitment to levels of reserve funds designated to sustain activity through just such an unpredictable threat.

The Furlough scheme was helpful, and the trustees discussed how best to utilise its support in March 2020. Two staff members were placed on furlough during April 2020 to allow time to judge how far the pandemic would affect our donor income. During August 2020 the trustees reluctantly decided that these staff members would be placed under redundancy consultation. This was before the extension of the furlough scheme had been announced. Having carried out a “going concern” exercise, and considering the extreme drop in income, staff were informed of redundancies on 27 August 2020. This put great pressure on our remaining staff who had to take on a wider range of responsibilities and activities. Nevertheless, we remained very active during the pandemic, switching much of our focus to communication on social media and our website with the aim of supporting people with MS, especially during the most difficult months at the height of the pandemic.

Active research projects also had to be adapted rapidly. Two major projects were suspended in line with NHS and NIHR policy to avoid bringing patients into hospital departments while the risk of infection was at its highest. Many clinical staff were re-deployed during the periods of highest intake of covid patients and outpatient clinics were largely suspended with patients being managed remotely by phone or by using on-line visual platforms where needed.

Our patient information and support activities had previously been run mostly as face-to-face groups, and these courses also had to be suspended in compliance with national Covid-19 guidelines for much of the year. Fortunately, we were able to move some of this work to virtual platforms so that they could continue. We increased the rate of social media posts to try and keep people up to date with the ever-changing picture especially during periods of lock-down. We were also able to move much of our fundraising appeals to on-line platforms such as Facebook.

In all, although the losses in terms of time and progress of research programmes and patient support programmes were significant, it was necessary to re-think many established procedures and practices, especially regarding fundraising and communications with people coping with MS during the pandemic.

2

M. S. Research Treatment and Education Limited

Chair's report

For the year ended 31 March 2021

Our 5-year development plan, set up in 2015 was coming to an end and the decision was made to suspend the development of the next plan until we were more able to assess the impact of the pandemic on our operations and how far they were affected by societal and operational changes more generally. During the period April 2020 to March 2021 therefore our attention focused on how to deliver support to people with MS remotely and in compliance with general regulations and clinical and scientific advice during periods of lockdown. We also took advice from University and NHS research managers where we had active research programmes as to how their organisations were coping with the pandemic and from national research support agencies such as NIHR on best procedures especially during periods of lockdown.

Date: 10 December 2021 Rosie Jones - Chair

3

M. S. Research Treatment and Education Limited

Report of the trustees

For the year ended 31 March 2021

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice - Accounting and Reporting by Charities (effective from January 2019).

1. Objectives and Activities

The focus of MS Research remains provision of grant funding for research projects and programmes that aim to advance the treatment and management of the condition Multiple Sclerosis. The charity also supports further development of some successful treatment strategies beyond the research phase, providing “real world” evidence to support the aims of promoting the introduction of better treatment strategies and encouraging NHS healthcare commissioners to fund the introduction of new treatments especially in areas of patient support and rehabilitation where research has shown benefit.

Supporting ongoing work where possible

The study (CHARMED MS, CHARactersation of Movement to predict Efficacy DBS in MS), is a multidisciplinary project based at The Brain Centre at North Bristol NHS Trust and University of the West of England. Researchers include MS and movement disorder specialists, software engineering and rehabilitation experts. Patient recruitment began in June 2019 but the study had to be suspended at the end of March 2020 as clinical research teams were advised not to bring patients recruited into research projects to hospital sites during periods of high pressure on NHS resources and general lockdown. This was compliant with general covid regulations, and the advice of NIHR (National Institute for Health Research) as well as local research management teams. CHARMED MS investigates identification of MS-related tremor characteristics that might benefit from DBS (Deep Brain Stimulation) by determining the key characteristics of tremor that respond to DBS. We were informed that recruitment for this study would probably be able to re-start in March 2021.

We also intended to continue to fund projects based at the University of Bristol’s Clinical Research Imaging Centre (CRIC) to extend the exploration of causes of debilitating fatigue in MS using functional MRI (fMRI) techniques. Recruitment for next phase studies were started in January 2020 but unfortunately, we were informed that the University of Bristol was closing the CRIC temporarily to non-covid research in March 2020. In August 2020 we were informed that all the CRIC research resources and staff would be withdrawn for the foreseeable future. We will seek to place functional fMRI research studies at other CRIC centres in the UK. We expect studies completed to date to be published during 2021/2022 and given the importance of the data obtained to date, sought assurance from the University of Bristol Pro Vice Chancellor and Head of Research for University Hospitals NHS Trust that data and resources would be made available to research staff at least until December 2020. This assurance was given in August 2020.

Our face-to-face patient support and education activities were also suspended in March 2020 although the FACETS fatigue management course was transferred to an on-line virtual format and groups continued through the year. Continence and impaired upper limb face to face activities could not be continued under the covid regulations and reorganisation of these and other virtual MS support programmes are being developed.

Angela Davies Smith who runs the FACETS courses continued to work on on-line FACETS support developments with the University of Bournemouth throughout the lock-down period and she also provided a series of on-line support seminars to enable clinical specialists to develop their own clinical FACETS programmes internationally.

4

M. S. Research Treatment and Education Limited

Report of the trustees

For the year ended 31 March 2021

Operations and staffing

During the periods of lock-down trustee meetings were held using email and zoom. A brief resume of these communications is outlined below. Important decisions were made regarding staffing. On 31 March 2020 the proposal was put to the trustees that two members of staff (Elizabeth Martens and Stephanie Crossland) be put on furlough until such time as future plans became clearer. The Vassall Centre remained open during lockdown (strictly adhering to Government guidelines) as many of the tenants offered essential services. However, MS Research closed our offices from 16 March 2020 and observed the Government lockdown guidelines throughout 2020 and into 2021. James Cox (Community Fundraiser) and Abi Wiltshire (Operations Manager) worked from home during the initial lockdown and returned to the office, with restrictions in place during June and July 2020. During subsequent local and national restrictions Abi worked from home and alone in the Vassall Centre office, when necessary. James Cox worked from home. As there were no public fundraising events during this period, James turned his attention to setting up on-line giving options and encouraging individuals to set up their own fundraising events.

As people were encouraged to return to work and the Vassall Centre re-opened more fully in August 2020, further decisions were made as to how to proceed. After much deliberation and discussion, the decision was made to offer redundancy to Stephanie Crossland and Liz Martens. Both accepted.

2. Governance and structure

The organisation is a company limited by guarantee, incorporated on 23 December 1994 and is governed by its Memorandum and Articles of Association. The company was registered with the Charity Commission on 12 January 1995. Since 2013 it has operated from offices at the Vassall Centre in Bristol, a barrier free workspace initially set up as a not-for-profit social concern in disused hospital buildings fully accessible to people who have disability.

The Charity’s Public Benefit statement set out in accordance with the Charity Commission's Guidelines has referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the Charity’s aims and objectives during this unusual time. This particularly includes seeking to make advice and patient support more readily available on-line to reach a wider audience of those who have MS and those who care for them. This includes extending advice and support sections on our website to help people through the difficult regulations imposed to help control spread of the virus, and to provide up to date bulletins on medical and scientific opinion on MS care and support as provided in a range of formal documents produced by government and their advisers, senior medical and scientific personnel, and other authoritative sources. Most NHS centres treating MS set up helplines so that those seeking help could get advice from medical, nursing or therapy practitioners remotely. Over time, telephone or virtual appointments became available as the NHS moved to minimal contact patient resources to avoid the spread of the virus. MSRTE offered suggestions as to how patients could make best use of the new approaches to patient support and advised looking to local MS teams for the best options to meet their medical support needs locally.

MS Research follows the Charity Commission’s guidance on trustee recruitment and are currently actively and consistently seeking new trustees. We periodically advertise using our website, social media forums, and national trustee recruitment sites such as Charity Job, REACH and trustees Unlimited as advised by NCVO. The chair of trustees has contacted several possible candidates during the year and held a preliminary interview with one interested party but in general people have been reluctant to take on new roles while pandemic restrictions limited travel and face to face discussion.

5

M. S. Research Treatment and Education Limited

Report of the trustees

For the year ended 31 March 2021

3. Achievements and performance

Like most organisations we had to cope with a continuously changing background to fundraising and normal operations. More emphasis was placed on on-line fundraising methods and the rate of information posts on all social media and our website were increased. The staff still working needed to adjust rapidly to new ways of operating and reaching supporters. Their response was admirable and slowly new donors were reached and new donor support methods were adopted including successfully encouraging remote fundraising using platforms such as Facebook Giving. This included some larger donations aimed at restoring work on the suspended research programmes under the online “Return to Research” campaign. Some donations were restricted to general or specific research programmes, and these are noted in the accounts. During June 2020 we received notification of a one fifth share of a large legacy. Although this estate is yet to be finalised an interim payment of £75,000 was paid to MS Research on 12 March 2021.

Aside from adapting to new ways of working around the difficulties in coping during the pandemic and supporting fewer staff, the trustees were also able to start discussions on future operational developments and fundraising approaches. Normally a 5-year plan is put in place as the previous planning and strategies close. On this occasion it was decided to delay any confirmation of plans for the next 5 years until we had a clearer idea of what funds might be available once the pandemic restrictions were removed. We anticipate that the next 5-year plan will commence during 2022 when it will be clearer whether any gaps or changes in research management in universities and the NHS have emerged.

Despite the very difficult environment created by the second Covid-19 lockdown, some evidence of increasing levels of donations and interest in new and possibly better working arrangements began to evolve.

Our “new look” website was launched in May 2020 enabling us to share more in-depth information, images and video as well as receive grant applications for research, treatment and education.

4. Financial review

Reserves Policy

Our policy on managing reserves has been two-fold, committed funds and contingency reserves:

  1. Committed funds: To keep in hand a sum of money to enable the completion of on-going research studies, or to initiate new studies with appropriate funds in hand to ensure there are no delays in starting or funding approved new research studies or to continue essential treatment and education programmes to the end of a financial year. These are referred to as committed funds. Funds committed to the Tremor study CHARMED MS in 2019/20 were only partially spent in the financial year 2020/21 as the project was put on hold during the pandemic lockdown period. The sum of £34,000 has been allocated to this project in the hope of being able to re-start it in 2021. As explained in "supporting ongoing work where possible" it was not possible to restart Charmed-MS in 2020/21 and discussions are still underway to decide how to move forward with this research project.

  2. Contingency reserves: To enable a basic office service to continue with the aim of promoting recovery or other actions as needed in the case of income failure. A contingency fund of £32,000 was agreed for skeleton office staffing, essential running costs and rent to ensure time for recovery in the case of the force majeure disruption of income. The charity also holds £14,000 in designated reserves for future projects and growth.

6

M. S. Research Treatment and Education Limited

Report of the trustees

For the year ended 31 March 2021

The charity held £76,562 in unrestricted general funds at the end of the year due to receipt of an interim legacy payment of £75,000 in March 2021. The final amount of the legacy is not yet known. When the estate and legacy payments are finalised the trustees will meet to determine how these funds will be allocated. Holdings in reserve are reviewed annually alongside the annual budget and a suitable sum agreed in line with our responsibilities and to meet our legal obligations.

Many areas of expenditure were difficult to predict, and income could not be estimated but we suggest these were realistic figures for the financial year in question and have enabled, alongside other measures, to maintain on-going work to continue despite a precipitous drop in income towards the end of the previous financial year and due to a second lockdown in 2020. Fortunately, notification of pending legacies helped to clarify how the year might end financially and what reliable predictions might be made although exact financial predictions could not be made.

Given that all our ongoing research programmes were halted during the pandemic, charges for research staff were also held over as agreed with the hosts of the research and under the guidance of NIHR to NHS research managers. This meant that research programmes previously agreed with the University of Bristol at CRIC Bristol did not start as the provisional start date was during the first national lockdown. In fact, the University of Bristol has now closed the CRIC to all non-covid research and disbanded the staff responsible for running a range of promising research projects including those we were preparing to fund.

Temporary suspension of the project CHARMED MS also occurred during the first lockdown and no patients were therefore recruited between November 2019 and July 2020. It was agreed with University of the West of England and MS Research that no charges would be made for their staff input to the project until it was up and running again. In fact, because of the risks to patients travelling and coming into the hospital environment, it was agreed that more time was needed to ensure appropriate safety for both NHS patients and staff. This turned out to be a wise move as covid levels began to rise again at the end of 2020 and a further lockdown was instigated in early 2021. The last invoice for all staff engaged in CHARMED MS is invoice No 369985 for 2019 to 2020 taking due payments up to the end of March 2020. No further invoices have been received. Regular meetings have continued to keep everyone involved updated on the CHARMED MS project status.

Other projects such as FACETS fatigue programmes did continue online during the year, and these are accounted for as payments to Angela Davies Smith up to March 2021.

Income was heavily impacted during the first lockdown in 2020 as many planned fundraising events were cancelled. When it was clear that lockdown would be lifted during the summer of 2020 MS Research posted a number of social media posts and newsletters encouraging people to start fundraising again and the income began to build up during late summer and autumn 2020.

Although for the saddest of reasons, our income was also boosted by several larger donations arising from legacies and the notification and part payment of a large legacy during March 2021. Our income for the year ending 31 March 2021 was £124,005, expenditure £60,226 leaving a surplus of £63,779.

In all we were heartened by the responses of our donors to our plea for fundraising and pleased to be able to catch up on donated income during this very unpredictable time. Similarly, our costs were reduced as we instigated redundancies following furlough and reduced our staff numbers from 4 to 2, both part time.

7

M. S. Research Treatment and Education Limited

Report of the trustees

For the year ended 31 March 2021

Statement of responsibilities of the trustees

The trustees (who are also directors of the charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the trustees are required to:

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Independent examiners

Godfrey Wilson Limited were re-appointed as independent examiners to the charitable company during the year and have expressed their willingness to continue in that capacity.

Approved by the trustees on 10 December 2021 and signed on their behalf by

Rosie Jones - Chair

8

Independent examiner's report

To the trustees of

M. S. Research Treatment and Education Limited

I report to the trustees on my examination of the accounts of M. S. Research Treatment and Education Limited (the charitable company) for the year ended 31 March 2021, which are set out on pages 10 to 22.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satisfied myself that the accounts of the charitable company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner’s statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Date: 10 December 2021 Rob Wilson FCA Member of the ICAEW For and on behalf of: Godfrey Wilson Limited

Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

9

M. S. Research Treatment and Education Limited

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2021

Restricted Unrestricted
Note
£
£
Income from:
Donations and legacies
3
-
123,989
Charitable activities
4
-
-
Investments
-
16
Total income
-
124,005
Expenditure on:
Raising funds
-
34,539
Charitable activities
-
25,687
Total expenditure
6
-
60,226
Net expenditure
-
63,779
Transfers between funds
-
-
Net movement in funds
9
-
63,779
Reconciliation of funds:
Total funds brought forward
10,500
92,783
Total funds carried forward
10,500
156,562
2021
Total
£
123,989
-
16
124,005
34,539
25,687
60,226
63,779
-
63,779
103,283
167,062
2020
Total
£
55,504
500
81
56,085
31,090
64,902
95,992
(39,907)
-
(39,907)
143,190
103,283

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 16 to the accounts.

10

M. S. Research Treatment and Education Limited

Balance sheet

As at 31 March 2021

Note
Fixed assets
Tangible assets
12
Current assets
Debtors
13
Cash at bank and in hand
Liabilities
Creditors: amounts falling due within 1 year
14
Net current assets
Net assets
15
Funds
16
Restricted funds
Unrestricted funds
Designated funds
General funds
Total charity funds
£
2,886
171,516
174,402
(7,949)
2021
£
609
166,453
167,062
10,500
80,000
76,562
167,062
2020
£
1,341
4,155
125,524
129,679
(27,737)
101,942
103,283
10,500
57,882
34,901
103,283

Total charity funds

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477(2), and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 10 December 2021 and signed on their behalf by

Rosie Jones - Chair

11

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

1. Accounting policies

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

M. S. Research Treatment and Education Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern. However, the COVID-19 pandemic has had a profound impact on the global economy, and has in turn affected the charity. The trustees have considered the impact of this issue on the charity’s current and future financial position. The charity held unrestricted net funds of £156,562 and a cash balance of £171,516 at 31 March 2021. The charity has taken measures to reduce costs and has also received notification of a substantial legacy following the year end. The trustees therefore consider that the charity is a going concern for a period of at least 12 months from the date on which these financial statements are approved.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from the government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executors to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probably when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have been met, then the legacy is treated as a contingent asset and disclosed if material.

12

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

1. Accounting policies (continued)

d) Donated services and facilities

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

e) Interest receivable

f) Funds accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

g) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

h) Allocation of support costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Governance costs are the costs associated with the governance arrangements of the charity, including the costs of complying with constitutional and statutory requirements and any costs associated with the strategic management of the charity’s activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the following basis, being the respective proportion of total costs:

2021 2020
Raising funds 57.3% 32.4%
Charitable activities 42.7% 67.6%

13

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

1. Accounting policies (continued)

i) Tangible fixed assets

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows: Computer equipment 4 years

Items of equipment are capitalised where the purchase price exceeds £500.

j) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

k) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

l) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

m) Redundancy and termination costs

Where an employee receives a termination benefit the full cost is recognised at the date the employee is notified.

n) Pension costs

The charity operates a defined contribution pension scheme for its employees. There are no further liabilities other than that already recognised in the SOFA.

o) Accounting estimates and key judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described below.

Depreciation

As described in note 1i to the financial statements, depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life.

14

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

2. Prior period comparatives: statement of financial activities

Income from:
Donations and legacies
Charitable activities
Investments
Total income
Expenditure on:
Raising funds
Charitable activities
Total expenditure
Net income/(expenditure) and net movement in funds
3.
Income from donations and legacies
Donations from online platforms
Donations from purchasing partners
Regular donations
One-off donations
Legacies
In memoriam
Coronavirus Job Retention Scheme
Prior period comparative
Donations from online platforms
Donations from purchasing partners
Regular donations
One-off donations
Legacies
In memoriam
Total income from donations and
legacies
Total income from donations and
legacies
Restricted
£
£
10,000
45,504
500
-
-
81
10,500
45,585
-
31,090
-
64,902
-
95,992
10,500
(50,407)
Restricted
£
£
-
8,568
-
9,219
-
20,198
-
3,846
-
75,000
-
622
-
6,536
-
123,989
Restricted
£
£
-
16,146
-
521
-
3,257
10,000
14,390
-
500
-
10,690
10,000
45,504
Unrestricted
Unrestricted
Unrestricted
2020
Total
£
55,504
500
81
56,085
31,090
64,902
95,992
(39,907)
2021
Total
£
8,568
9,219
20,198
3,846
75,000
622
6,536
123,989
2020
Total
£
16,146
521
3,257
24,390
500
10,690
55,504

15

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

4. Income from charitable activities

There was no income from charitable activities during the year (2020: restricted grants £500).

5. Government grants

The charity receives government grants, defined as funding from the Coronavirus Job Retention Scheme to fund charitable activities. The total value of such grants in the period ending 31 March 2021 was £6,536 (2020: nil). There are no unfulfilled conditions or contingencies attaching to these grants in 2020/21.

6. Total expenditure

Total expenditure
Grants payable (note 7)
Staff costs (note 10)
Online platform fees
Fundraising event costs
Subscriptions
Premises costs
Office running costs
Accountancy
Bank charges
Travel and subsistence
Depreciation
Sub-total
Allocation of support and governance costs
Total expenditure
Raising
funds
£
-
15,409
282
270
-
-
-
-
-
-
-
15,961
18,578
34,539
Charitable
activities
£
£
5,648
-
6,349
14,930
-
-
-
-
-
676
-
10,060
-
2,233
-
3,558
-
187
(127)
19
-
732
11,870
32,395
13,817
(32,395)
25,687
-
Support and
governance
costs
2021
Total
£
5,648
36,688
282
270
676
10,060
2,233
3,558
187
(108)
732
60,226
-
60,226

Total governance costs in the period were £2,340 (2020: £1,990).

16

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

6.
Total expenditure (continued)
Prior period comparative
Grants payable (note 7)
Other activity costs
Staff costs (note 10)
Online platform fees
Fundraising event costs
Fundraising consultancy
Subscriptions
Premises costs
Office running costs
Accountancy
Bank charges
Travel and subsistence
Depreciation
Sub-total
Allocation of support and governance costs
Total expenditure
Raising
funds
£
-
-
19,452
526
610
25
-
-
-
-
-
-
-
20,613
10,477
31,090
Charitable
activities
£
33,786
133
7,237
-
-
-
-
-
-
-
-
1,875
-
43,031
21,871
64,902
£
-
-
12,881
-
-
-
540
10,046
2,737
4,604
185
624
731
32,348
(32,348)
-
Support and
governance
2020
Total
£
33,786
133
39,570
526
610
25
540
10,046
2,737
4,604
185
2,499
731
95,992
-
95,992

7. Grants payable

Grants made during the year were as follows:

Grants payable
Grants made during the year were as follows:
Grants to organisations:
North Bristol NHS
Grants to individuals:
No research and education grants made to individuals (2020: 3)
2021
£
5,648
-
5,648
2020
£
31,320
2,466
33,786

17

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

8.
Grant commitments
Grants payable to organisations:
Grant commitments brought forward
Grants committed to during the period
Grants paid during the period
Grant commitments carried forward
Grants payable to individuals:
Grant commitments brought forward
Grants committed to during the period
Grants paid during the period
Grant commitments carried forward
9.
Net movement in funds
This is stated after charging:
Depreciation
Operating lease payments
Trustees' remuneration
Trustees' reimbursed expenses*
2021
£
22,118
5,648
(27,766)
-
-
-
-
-
2021
£
732
7,762
Nil
Nil
2020
£
3,286
31,320
(12,488)
22,118
-
2,466
(2,466)
-
2020
£
731
7,760
Nil
101

*No trustees received reimbursed expenses during the year (2020: one trustee received reimbursed travel costs)

10. Staff costs and numbers

Staff costs were as follows:

Salaries and wages
Pension costs
2021
£
36,160
528
36,688
2020
£
39,042
528
39,570

No employee earned more than £60,000 during the year.

Two employees were made redundant during the year. Redundancy payments which totalled £890 have been included within the salaries and wages figure above. All redundancy and termination costs were statutory, were agreed and paid during the year, were funded from general unrestricted reserves and there were no amounts outstanding at 31 March 2021.

18

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

10. Staff costs and numbers (continued)

The key management personnel of the charitable company comprise the trustees and Fund Development Manager. The total employee benefits of the key management personnel were £18,125 (2020: £18,125).

Average head count 2021
No.
3.0
2020
No.
4.5

11. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

12. Tangible fixed assets

Tangible fixed assets
Cost
At 1 April 2020 and at 31 March 2021
Depreciation
At 1 April 2020
Charge for the year
At 31 March 2021
Net book value
At 31 March 2021
At 31 March 2020
Debtors
Prepayments
Other debtors
£
1,219
305
305
610
609
914
Computer
equipment
£
1,705
1,278
427
1,705
-
427
2021
£
2,886
-
2,886
Fixtures
and fittings
Total
£
2,924
1,583
732
2,315
609
1,341
2020
£
2,927
1,228
4,155

13. Debtors

19

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

14. Creditors : amounts due within 1 year

Creditors : amounts due within 1 year
Trade creditors
Grant commitments (note 8)
Accruals
Pension
2021
£
4,860
-
3,036
53
7,949
2020
£
3,573
22,118
1,993
53
27,737

15. Analysis of net assets between funds

Tangible fixed assets
Current assets
Current liabilities
Net assets at 31 March 2021
Prior year comparative
Tangible fixed assets
Current assets
Current liabilities
Net assets at 31 March 2020
£
-
10,500
-
10,500
£
-
10,500
-
10,500
Restricted
funds
Restricted
funds
£
-
80,000
-
80,000
£
-
80,000
(22,118)
57,882
Designated
funds
Designated
funds
£
609
83,902
(7,949)
76,562
£
1,341
39,179
(5,619)
34,901
Unrestricted
funds
Unrestricted
funds
Total
funds
£
609
174,402
(7,949)
167,062
Total
funds
£
1,341
129,679
(27,737)
103,283

20

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

16. Movements in funds

Restricted funds
British Science Week Grant
The Hollister Research Fund
Total restricted funds
Designated funds:
Contingency fund
Specific projects
Future projects & growth
Total designated funds
General funds
Total unrestricted funds
Total funds
Unrestricted funds
At 1 April
2020
£
500
10,000
10,500
32,000
11,882
14,000
57,882
34,901
92,783
103,283
Income
£
-
-
-
-
-
-
-
124,005
124,005
124,005
£
-
-
-
-
-
-
-
(60,226)
(60,226)
(60,226)
Expenditure
Transfers
between
funds
£
£
-
500
-
10,000
-
10,500
-
32,000
22,118
34,000
-
14,000
22,118
80,000
(22,118)
76,562
-
156,562
-
167,062
At 31 March
2021
Transfers
between
funds
£
£
-
500
-
10,000
-
10,500
-
32,000
22,118
34,000
-
14,000
22,118
80,000
(22,118)
76,562
-
156,562
-
167,062
At 31 March
2021
10,500
32,000
34,000
14,000
80,000
76,562
156,562
167,062

Purposes of restricted funds

British Science Week To fully fund a Digesting Science event to educate children and families who Grant are directly affected by a family member living with MS.

The Hollister Research Fund

To fully fund or contribute to medical research to benefit those living with MS.

Purposes of designated funds

Contingency fund

Represents money held in a reserve account in case of an unexpected shortfall between income and expenditure in future years.

Specific projects Represents funds intended for specific projects where the criteria has not been met to accrue the expenditure.

Future projects & growth Represents funds set aside for future projects and charity growth.

21

M. S. Research Treatment and Education Limited

Notes to the financial statements

For the year ended 31 March 2021

16. Movements in funds (continued)

Prior year comparative
Restricted funds
British Science Week Grant
The Hollister Research Fund
Total restricted funds
Designated funds:
Contingency fund
Specific projects
Future projects & growth
Total designated funds
General funds
Total unrestricted funds
Total funds
Unrestricted funds
At 1 April
2019
£
-
-
-
26,000
34,000
14,000
74,000
69,190
143,190
143,190
Income
£
500
10,000
10,500
-
-
-
-
45,585
45,585
56,085
£
-
-
-
-
(22,118)
-
(22,118)
(73,874)
(95,992)
(95,992)
Expenditure
Transfers
between
funds
£
£
-
500
-
10,000
-
10,500
6,000
32,000
-
11,882
-
14,000
6,000
57,882
(6,000)
34,901
-
92,783
-
103,283
At 31 March
2020
Transfers
between
funds
£
£
-
500
-
10,000
-
10,500
6,000
32,000
-
11,882
-
14,000
6,000
57,882
(6,000)
34,901
-
92,783
-
103,283
At 31 March
2020
10,500
32,000
11,882
14,000
57,882
34,901
92,783
103,283

17. Operating lease commitments

The charity had operating leases at the year end with total future minimum lease payments as follows:

Amount falling due:
Within 1 year
Within 1 - 5 years
2021
£
7,762
-
7,762
2020
£
7,762
-
7,762

18. Related party transactions

There were no related party transactions during the period.

22